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INTRODUCTION 
 Acute Myocardial infarction is the most common and most serious life 
threatening illness that causes more deaths and disability and incurs greater 
economic costs than any other illness in the world. The mechanism responsible 
for infarction related arrhythmias include autonomic nervous system 
imbalance, electrolyte disturbances, ischemia and slowed condition in the 
zones of ischemic myocardium. 
 Arrhythmias have been noted in 70 to 95% of patients with Acute 
Myocardial infarction. Many arrhythmias may occur prior to hospitalization 
and thus the overall incidence of arrhythmias in acute myocardial infarction 
may actually be 100%. 
 Arrhythmias are responsible for serious hemodynamic disturbances. The 
most significant consequence of cardiac arrhythmias is fall in cardiac output 
and B.P. This may precipitate or aggravate congestive cardiac failure. More 
than 60% of deaths associated with acute myocardial infarction occur within 1 
hour of the event and are attributable to malignant arrhythmias usually 
ventricular fibrillation. 
 Careful monitoring of cardiac rhythm and prompt treatment of 
arrhythmias have sharply reduced the incidence of in-hospital deaths from 
arrhythmias. 
 Prior to the advent of coronary care units, treatment of acute myocardial 
infarction was towards healing of the infarct preventing cardiac rupture and 
management of pulmonary or systemic embolism. Subsequently the major 
emphasis of the therapeutic strategy is on the prophylaxis and aggressive 
treatment of arrhythmias. 
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 Lown and his colleagues, through their provocative works, proved that 
intensive coronary care should be attempted in order to prevent the 
development of serious ventricular arrhythmias, which serves to reduce the 
mortality from acute myocardial infarction. This realisation led to the 
proliferation of mobile coronary care units, ICCU units and intermediate care 
or step down units. 
 During the past 3 decades, the mortality of patients with acute 
myocardial infarction treated in intensive coronary care units has declined from 
30% to about 15%. The reduction in mortality has resulted from the elimination 
of primary arrhythmias as a cause of death.  Intensive coronary care units allow 
continuous monitoring of cardiac rhythm by highly trained personnel, 
administer immediate support, treatment and prophylaxis of arrhythmias and 
use specialised cardiac interventions. 
 Anterior wall Myocardial infarction is the most common presentation of 
acute myocardial infarction. Left anterior descending artery is the most 
frequent culprit vessel. The incidence type and severity of arrhythmias varies 
with the area of the infarct. Tachyarrhythmias are most commonly seen in 
anterior wall myocardial infarction while Bradyarrhythmias occur frequently in 
inferior wall myocardial infarction. The overall incidence of arrhythmias and 
their resultant mortality is more with anterior wall myocardial infarction.  
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AIM OF THE STUDY 
 The aim of the study is to analyse : 
1. The incidence of different types of arrhythmias in acute anterior 
wall myocardial infarction in 100 consecutive patients admitted 
to intensive coronary care unit of Govt. Stanley Hospital. 
2. Correlation of each type of arrhythmia with the location and 
extent of acute anterior wall myocardial infarction. 
3. To evaluate the role of age, sex and other risk factors in relation 
to the various types of arrhythmias. 
4. To interpret the prognostic factors for various arrhythmias and 
their outcome. 
5. To assess the effect of arrhythmias on the morbidity and 
mortality of patients with acute anterior wall myocardial 
infarction. 
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REVIEW OF LITERATURE 
Anatomy and physiology of the conducting system 
 The rate and rhythm of the heart are controlled by the sino-atrial node 
(SA node), which is situated in the wall of the right atrium to the right of the 
superior vena caval orifice. The sinus impulse leaves the SA node and spreads 
through the atrial muscle; this atrial activation is reflected by the P wave of the 
electrocardiogram. The sinus impulse eventually reaches the AV node, which is 
situated in the right atrium above the tricuspid valve and just to the right of the 
interatrial septum. After a delay at the AV node (reflected in the 
electrocardiogram as the greater part of the P-R interval) the impulse travels 
down the bundle of His, bundle branches and Purkinje network system. The 
bundle of His passes horizontally to the left from the AV node, pierces the 
membranous interventricular septum  and divides into right and left bundle 
branches. These pass down on either side of the muscular interventricular 
septum and finally divide into the Purkinje network fibres, which proceed 
vertically to the surface of the heart from the endocardium to the epicardium. 
 The SA node is mainly under the influence of the vagus nerve, and 
normal variations in heart rate are effected mainly by variations in vagal tone. 
An increase in vagal tone slows the heart; a decrease in vagal tone accelerates 
the heart. The SA node is also influenced to a lesser degree by variations in 
sympathetic tone. 
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The pacemakers of the heart 
 The heart has many potential pacemaking cells. These are situated in the 
SA node, the AV node, the bundle of His, the atria and the ventricles (every 
Purkinje cell is a potential pacemaking cell). The SA node has the fastest 
inherent discharge rate, which usually ranges from 70 to 80 beats per minute. 
The inherent rate of potential AV nodal pacemaking cells is about 60 beats per 
minute. The inherent rate of pacemaking cells in the bundle of His is about 50 
beats per minute. The inherent rate of the Purkinje cells of the ventricular 
muscle is about 30-40 heats per minute. In other words, the more distally a 
potential pacemaker is situated from the SA node, the slower is its inherent 
discharge rate. 
 This ensures that there is only one pacemaker which is normally in 
control of the heart, for, otherwise, chaos would reign supreme. The concept of 
protection is one of the most important principles governing electrophysiology. 
Not only does it ensure that there is only one pacemaker governing and in 
control of the heart, but it permits a slower pacemaker to take over the 
pacemaking function of the heart when the fastest pacemaker defaults. Thus, if 
the sinus pacemaker should fail to reach a slower subsidiary pacemaker, due, 
for example, to marked sinus bradycardia, SA block or AV block, a slower 
pacemaker in the ventricles will take over the pacemaking function, 
manifesting as a ventricular escape rhythm. 
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Classification of arrhythmias0  
 Abnormal rhythms occur as primary and secondary disorders. Primary 
disorders of rhythm reflect a basic, essential abnormality. Secondary disorders 
of rhythm only occur as a result of, and secondary to, a primary disorder. 
The primary disorders of rhythm 
 The primary disorders of rhythm may, in simplified form, be classified 
into two major categories. 
1. Disturbances of impulse formation 
2. Disturbances of impulse conduction. 
Disturbances of impulse formation 
 Sinus rhythms 
 Sinus arrhythmia 
 Sinus tachycardia 
 Sinus bradycardia 
Ectopic atrial rhythms 
 Atrial extrasystoles 
 Paroxysmal atrial tachycardia 
 Atrial fibrillation 
 Atrial flutter 
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AV nodal rhythms 
AV nodal extrasystoles 
Extrasystolic-paroxysmal-AV nodal tachycardia 
Idionodal tachycardia 
Ventricular rhythms 
 Ventricular extrasystoles 
 Extrasystolic ventricular tachycardia 
 Idioventricular tachycardia 
 Ventricular flutter 
 Ventricular fibrillation 
 Ventricular parasystole 
Disturbance of impulse conduction 
SA Block 
Intra atrial block 
Atrio ventricular dissociation 
Atrio ventricular blocks 
 I° AV Block 
 II° AV Block  Mobitz type I AV Block 
    Mobitz type II AV Block 
 III° AV Block (Complete heart block) 
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Bundle branch block 
 LAHB 
 LPHB 
 LBBB 
 RBBB 
 B/L BBB 
The Secondary disorders of rhythm 
(i) Escape rhythms 
 - Atrial escape 
 - AV nodal escape 
 -  Ventricular escape 
(ii) AV dissociation 
(iii) Phasic aberrant ventricular conduction 
ARRHYTHMIAS IN MYOCARDIAL INFARCTION 
Patients with myocardial infarction can experience a wide range of 
arrhythmias and conduction abnormalities, from transient and relatively 
innocuous sinus bradycardia to life-threatening ventricular fibrillation. 
Supraventricular tachyarrhythmias (most commonly, atrial fibrillation) 
generally occur with a rapid heart rate and may cause or exacerbate ischemia, 
provoke a serious sustained ventricular tachyarrhythmia, or induce or worsen 
heart failure. However, such arrhythmias are usually not life-threatening.  
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Ventricular tachyarrhythmias may be asymptomatic and relatively 
innocuous (eg, ventricular premature beats), asymptomatic but of prognostic 
importance (eg, nonsustained ventricular tachycardia), or sustained and 
symptomatic or life-threatening (eg, sustained monomorphic or polymorphic 
ventricular tachycardia or ventricular fibrillation).  
Bradyarrhythmias that result from sinoatrial (SA) nodal dysfunction or 
from abnormalities of atrioventricular (AV) nodal or His-Purkinje system 
disease include second-degree and third-degree (complete) heart block.  
Etiology of supraventricular arrhythmias 
Supraventricular arrhythmias are relatively common in the preinfarction 
period. Explanations for their frequent occurrence include: 
(1) atrial ischemia and, rarely, infarction 
(2) stretch and distention of the atrial myocardium resulting from 
elevated atrial pressure 
(3) irritation of the atrial myocardium resulting from pericarditis 
(4) elevated sympathetic tone and an increase in circulating 
catecholamines, and  
(5) vagal activation and an increase in parasympathetic tone, especially 
with an inferior wall infarction.  
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Sinus bradycardia 
Sinus bradycardia occurs in 16% to 25% of patients with acute 
myocardial infarction, particularly of the inferior or posterior wall1. It is most 
often transient, resulting from an increase in vagal tone. A decrease in 
myocardial efficiency and a reduction in cardiac output may cause 
hemodynamic symptoms, including exacerbation of ischemia, reduced 
mentation, congestive heart failure (CHF), and a more serious escape rhythm.  
No specific therapy is needed for asymptomatic sinus bradycardia. If 
symptoms of hemodynamic compromise or ischemia occur, intravenous 
atropine sulfate, 0.6 to 1 mg, is usually effective. Persistent bradycardia 
warrants consideration of temporary pacing, which also may be necessary if the 
patient requires therapy with drugs that may further depress sinus node 
automaticity, particularly beta blockers. Since sinus bradycardia usually 
resolves, long-term pacing is rarely needed.  
Sinus tachycardia 
About 30% of patients experience sinus tachycardia following 
myocardial infarction2. It represents an appropriate physiologic response to left 
ventricular dysfunction, CHF, or stimulation and overactivity of the 
sympathetic nervous system. Treatment therefore is targeted at the underlying 
cause: angiotensin converting enzyme inhibitors, digoxin and diuretics for CHF 
and beta blockers for a primary increase in sympathetic output or an increase in 
circulating catecholamines. The dose is adjusted as the heart rate slows.  
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Atrial arrhythmias 
About 10% to 20% of patients with myocardial infarction experience 
atrial arrhythmias. These generally occur within 24 hours of infarction3.  
Atrial fibrillation 
Atrial fibrillation is seen in 10% to 15% of patients with myocardial 
infarction4,6, most commonly in those who have significant left ventricular 
dysfunction and CHF. The presence of atrial fibrillation in patients with 
myocardial infarction increases mortality during and after hospitalization 
(relative risk, 1.7). This increase is due not to the arrhythmia itself but to 
factors associated with it, particularly left ventricular dysfunction, CHF, and 
cardiogenic shock5,6.  
Initial treatment of atrial fibrillation depends on the clinical situation and 
associated symptoms. Often, the arrhythmia is only transient and requires no 
therapy; even when persistent, it generally responds to appropriate treatment. 
Heparin therapy should be initiated soon after onset of atrial fibrillation, 
because anticoagulation reduces the small risk of embolism and eliminates 
concern about reversion within 48 hours.  
Prompt control of the heart rate is essential; an AV nodal blocking agent 
should be given intravenously--preferably a beta blocker or, if contraindicated, 
verapamil hydrochloride or diltiazem hydrochloride. Digoxin is not likely to 
slow the heart rate promptly but may be of use when atrial fibrillation is due to 
CHF, since digoxin therapy improves left ventricular function and 
hemodynamics and may result in reversion of atrial fibrillation and restoration 
of normal sinus rhythm.  
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Electrical cardioversion to restore sinus rhythm is indicated in patients 
with severe hemodynamic compromise or refractory symptoms of ischemia due 
to atrial fibrillation. When atrial fibrillation persists, reversion with 
antiarrhythmic therapy should be attempted. Although intravenous ibutilide 
fumarate has been beneficial for reverting new on set atrial fibrillation in about 
30% to 40% of patients, its efficacy and safety in patients with myocardial 
infarction have not been well studied7. Its major side effect is torsades de 
pointes; whether patients who have had a recent myocardial infarction are at 
increased risk for this complication is uncertain.  
Despite concerns raised by the Cardiac Arrhythmia Suppression Trial 
(CAST) about long-term use of class I antiarrhythmic agents in patients with 
myocardial infarction, these drugs are often beneficial for acute reversion of 
atrial fibrillation. In many cases, a single large dose of such a drug results in 
reversion within 2 or 3 hours8. If long-term therapy is necessary, the risks 
associated with the class I antiarrhythmic agents, particularly the class IC 
agents, may outweigh the benefits of reversion and prevention of atrial 
fibrillation. In such cases, sotalol hydrochloride, a drug with class III and beta-
blocking activity, is an appropriate first-line agent, since it may prevent atrial 
fibrillation in patients with myocardial infarction and is safe in this setting9.  
Amiodarone hydrochloride is also very effective for atrial fibrillation 
and is not associated with increased mortality in patients with myocardial 
infarction according to the European Myocardial Infarct Amiodarone Trial10  
and the Canadian Amiodarone Myocardial Infarction Arrhythmia Trial11. In 
patients in whom the use of any antiarrhythmic drug is a concern, a reasonable 
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approach is maintenance of atrial fibrillation with the use of an AV nodal 
blocking drug (especially a beta blocker) and long-term anticoagulation with 
warfarin sodium. 
Atrial flutter 
Atrial flutter is not commonly seen in patients with myocardial 
infarction, and after reversion it is not likely to recur. As with atrial fibrillation, 
the first step in management is to slow the heart rate, which can often be 
achieved with an AV nodal blocking agent. If this is not possible or if atrial 
flutter is accompanied by symptoms, electric cardioversion is highly effective. 
An alternative therapy, particularly for asymptomatic atrial flutter, is 
intravenous ibutilide, which is effective in reverting atrial flutter and restoring 
sinus rhythm in about 60% of patients.  
Since atrial flutter is not likely to recur, long-term suppression is 
unnecessary. However, if atrial flutter does recur and is accompanied by 
symptoms, long-term suppressive therapy is indicated. Concern about the use 
of class I antiarrhythmic agents, particularly class IC drugs, in patients with a 
recent myocardial infarction has resulted in greater reliance on the class III 
agents. Use of radiofrequency catheter ablation, which is an effective approach 
for the prevention and possible cure of atrial flutter, is increasing. However, its 
use and role in patients with a recent myocardial infarction have not been 
evaluated.  
Etiology of ventricular arrhythmias 
Several factors account for the high incidence of ventricular arrhythmias 
after myocardial infarction:  
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• Myocardial damage resulting in variable and nonuniform changes in 
impulse conduction and membrane repolarization  
• Hypoxia and acidosis  
• Activation of the sympathetic nervous system and resulting sympathetic 
vagal imbalance  
• Spontaneous, mechanically induced, or pharmacologically induced 
reperfusion, which can result in arrhythmia  
Ventricular premature beats of various frequencies are observed in up to 
90% of patients with myocardial infarction12,13. Nonsustained ventricular 
tachycardia occurs in up to 40% of such patients, and sustained ventricular 
tachycardia or ventricular fibrillation each occurs in about 3% to 5%. Mortality 
in the immediate postinfarction period, as well as during the first year after 
myocardial infarction, is most often due to sudden death from ventricular 
fibrillation.  
Ventricular premature beats 
Ventricular premature beats are usually asymptomatic, and it appears 
that isolated premature beats themselves in the setting of acute myocardial 
infarction, regardless of frequency or multiformity, are not associated with an 
increased risk of sustained ventricular tachyarrhythmia. Therefore, short-term 
therapy is not recommended unless the frequency of premature beats results in 
symptoms or hemodynamic instability or triggers more serious arrhythmia. In 
such situations, lidocaine hydrochloride is the drug of choice. Alternatively, 
intravenous procainamide hydrochloride  may be used.  
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Long-term antiarrhythmic therapy for ventricular premature beats is 
potentially hazardous and therefore is not indicated. A number of studies, 
including CAST14 and the Survival With Oral d-Sotalol (SWORD) trial15, have 
established that such therapy increases mortality.  
Ventricular tachycardia 
Ventricular tachycardia of several types may be seen in up to 40% of 
patients after myocardial infarction. 
Types: Accelerated idioventricular tachycardia, with a rate of 50 to 120 
beats per minute, results from either 
(1) failure or structural damage of the SA or AV nodal pacemaker or 
enhanced vagal tone leading to depression of nodal automaticity and function 
and an escape ventricular focus or  
(2) an abnormal ectopic focus within the ventricle, which assumes the 
role as dominant pacemaker. This arrhythmia most often occurs during 
reperfusion following thrombolytic therapy, especially when such agents are 
given early in the course of acute myocardial infarction16.  
When accelerated idioventricular tachycardia results from failure of 
proximal pacemakers, it represents a stable rhythm. However, when this 
arrhythmia is due to an ectopic focus, it is potentially unstable; the rate may 
become rapid, requiring the same therapy as for sustained ventricular 
tachycardia.  
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Accelerated idioventricular tachycardia due to an escape rhythm 
requires no treatment when it is stable and without hemodynamic symptoms. If 
symptoms are present, atropine therapy may be effective when enhanced vagal 
tone is the cause, or a temporary pacemaker may be indicated. An 
antiarrhythmic agent, particularly lidocaine, should not be given, because 
suppression may result in a profound sinus or junctional bradycardia or even 
asystole. Sympathetic stimulation with isoproterenol hydrochloride or 
epinephrine increases the pacemaker rate but has the potential to accelerate the 
rate in an unpredictable way.  
Nonsustained ventricular tachycardia consists of three or more 
successive ventricular beats lasting up to 30 seconds, with rates greater than 
120 beats per minute. Sustained ventricular tachycardia lasts more than 30 
seconds or is terminated in less than 30 seconds because of hemodynamic 
compromise. In polymorphic ventricular tachycardia, the QRS morphology 
and RR intervals are variable during each episode, while in monomorphic 
ventricular tachycardia, the QRS complexes are uniform and the RR intervals 
are fairly uniform, although slight variability may be present.  
Management: The approach to evaluation and treatment of ventricular 
tachycardia depends upon several factors:  
(1) Timing: Sustained ventricular tachycardia occurring within 48 hours 
of myocardial infarction, seen in 2% of patients, is often transient and is not 
associated with long-term risk of sudden cardiac death17. Only short-term 
suppression (generally 2 days) with an intravenous antiarrhythmic agent such 
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as lidocaine, procainamide, or bretylium tosylate is required. Amiodarone is 
frequently effective and may be used after other agents have been tried, 
particularly if lidocaine or procainamide has been ineffective18.  
When sustained ventricular tachycardia occurs more than 48 hours after 
acute myocardial infarction in a patient who is otherwise in stable condition 
and without evidence of CHF or ischemia, aggressive therapy with an 
antiarrhythmic drug or an implantable cardioverter-defibrillator is required.  
(2) Morphology: Polymorphic ventricular tachycardia, seen in 2% of 
patients with myocardial infarction, is often rapid, symptomatic, and 
hemodynamically and electrically unstable19. It is potentially life-threatening, 
since it may herald the occurrence of ventricular fibrillation. Polymorphic 
ventricular tachycardia is commonly associated with underlying and ongoing 
(overt or silent) ischemia, which warrants the use of anti-ischemic medication 
or revascularization with either percutaneous transluminal coronary angioplasty 
or coronary artery bypass grafting if critically stenotic lesions are present. On 
occasion, placement of an intra-aortic balloon pump is useful. If ventricular 
tachycardia recurs despite effective control of ischemia, long-term 
antiarrhythmic therapy or an implantable cardioverter-defibrillator is indicated. 
Monomorphic ventricular tachycardia is most often due to a reentrant 
mechanism and is the result of severe myocardial damage and scar formation. 
When rapid, symptomatic, or hemodynamically unstable, this arrhythmia 
requires prompt electric reversion. If ventricular tachycardia recurs despite 
lidocaine therapy, administration of amiodarone, procainamide, or bretylium 
can be tried. In some patients, intravenous beta-blocker therapy has been 
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effective in preventing recurrent arrhythmia, especially if an associated sinus 
tachycardia preceded the ventricular tachycardia episode.  
Overdrive pacing with use of a temporary pacemaker wire has also been 
of benefit in selected patients. It may be useful for prevention of arrhythmia, 
especially in the setting of bradycardia due to AV block or sinus node 
dysfunction.  
Long-term therapy is indicated only if the ventricular tachycardia occurs 
more than 48 hours after the onset of myocardial infarction in a patient who is 
otherwise in stable condition or if it has been recurrent or difficult to suppress.  
(3) Nonsustained versus sustained: Short-term therapy for sustained 
ventricular tachycardia is often necessary, and long-term therapy for prevention 
is occasionally indicated. Nonsustained ventricular tachycardia occurring 
during acute myocardial infarction may indicate a potential for sustained 
ventricular tachycardia or ventricular fibrillation, but it is uncertain whether 
prophylactic therapy, aimed at suppression of the arrhythmia, will prevent a 
sustained episode. In some situations, suppressive therapy with intravenous 
drugs (lidocaine, procainamide, bretylium, or amiodarone) is indicated; for 
example, nonsustained ventricular tachycardia that occurs in association with 
evidence of ongoing ischemia (electrocardiographic [ECG] changes and 
symptoms), that produces symptoms or hypotension, or that is polymorphic, 
rapid and frequent, or of long duration. In some patients, intravenous or oral 
beta-blocker therapy may be effective. Infrequently, overdrive pacing is needed 
to suppress this arrhythmia.  
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Therapy for nonsustained ventricular tachycardia that occurs more than 
48 hours after the acute event is problematic. Although this arrhythmia is 
linked to an increased risk of sudden death during the first 6 to 12 months after 
myocardial infarction20,21, especially when associated with a reduced left 
ventricular ejection fraction (<40%), there are no data to support that therapy 
directed at suppression of nonsustained ventricular tachycardia prevents sudden 
death22. In CAST14, only 20% of the patients had nonsustained ventricular 
tachycardia and only 10% had more than one run of ventricular tachycardia in 
24 hours.  
A proposed approach to management is further risk stratification to 
identify patients who are truly at high risk (ie, those with multiple risk factors, 
including positive late potentials on a signal-averaged ECG, absent heart rate 
variability, QT dispersion on the 12-lead ECG, or ventricular tachycardia 
induced with electrophysiologic study). Therapy with an antiarrhythmic agent, 
primarily sotalol or amiodarone, or with an implantable cardioverter-
defibrillator should be reserved for such high-risk patients.  
Ventricular fibrillation 
This rapid, disorganized arrhythmia produces no uniform ventricular 
contraction, no effective cardiac output, and no recordable blood pressure. The 
incidence of ventricular fibrillation is highest during the first 24 to 48 hours, 
particularly within the first 4 hours, after the acute event, and may occur in up 
to 5% of patients17. Prompt cardiopulmonary resuscitation and defibrillation 
(the only definitive treatment) are essential for survival. Although benefits are 
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uncertain, antiarrhythmic therapy with lidocaine, procainamide, or bretylium 
can be administered for recurrent ventricular fibrillation before subsequent 
shocks are delivered. These agents are usually continued for up to 48 hours 
after the event. The role of intravenous amiodarone is currently being studied 
in a number of prospective trials. Intravenous beta-blocker therapy 
administered at the time of presentation of acute myocardial infarction reduces 
the incidence of ventricular fibrillation during myocardial infarction23. In some 
patients, intravenous beta-blocker therapy prevents recurrent episodes. The 
capricorn trial36 (carvedilol post infarct survival control in left ventricular 
dysfunction study) proposed that carvedilol suppresses atrial and ventricular 
arrhythmias in patients with AMI. 
Ventricular fibrillation occurring within 48 hours of myocardial 
infarction is not predictive of higher mortality during the first year after 
infarction17. In contrast, when ventricular fibrillation occurs after 48 hours in a 
patient who is in clinically stable condition and free of ischemia, CHF, or an 
electrolyte imbalance, it is considered a primary event, and 
electrophysiologically guided pharmacologic therapy, empirical amiodarone 
therapy, or use of an implantable cardioverter-defibrillator is necessary. But 
prophylactic ICD therapy has not been found to reduce overall mortality in 
high risk patients with MI37. 
Conduction abnormalities and bradyarrhythmias 
Conduction abnormalities and bradyarrhythmias are frequent 
complications of acute myocardial infarction. They are most often transient, 
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requiring no specific short- or long-term therapy. When symptoms occur, a 
temporary pacemaker is important, and if they persist, a permanent pacemaker 
may be necessary. The availability of external pacemakers has resulted in a 
decrease in the need for prophylactic pacemakers, especially in view of the 
complications associated with insertion of temporary electrode catheters. The 
American College of Cardiology/American Heart Association (ACC/AHA) 
guidelines24 for the management of patients with acute myocardial infarction 
include the indications for therapy for conduction abnormalities and 
bradycardia. 
Abnormalities in SA or AV nodal function or intraventricular conduction may 
be attributed to one of the following:  
• An increase in parasympathetic tone commonly associated with an 
inferior wall myocardial infarction  
• An increase in extracellular potassium, which can cause slowing of 
impulse conduction  
• Local release and buildup of adenosine, a metabolite of adenosine 
triphosphate breakdown, which slows the velocity of impulse 
conduction through the AV node  
• Ischemia, which results in transient or permanent structural changes of 
the tissues surrounding the SA and AV junctions  
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Incidence of AV block 
Most of the available data regarding heart block in acute myocardial 
infarction are from studies performed in the prethrombolytic era, but the 
incidence of AV block among patients treated with a thrombolytic agent 
appears to be similar to that among untreated patients.  
First-degree AV block occurs in 4% to 14% of patients with acute 
myocardial infarction. Most often the block is within the AV node.  
Mobitz type I second-degree block is observed in up to 10% of patients, 
but it is usually transient, resolving within 72 hours postinfarction25,26. The 
block is located within the AV node and is most often caused by an increase in 
vagal tone or, less commonly, ischemia of the AV junction. It is more 
commonly seen with inferior wall myocardial infarction than with anterior wall 
involvement.  
Mobitz type II second-degree block occurs in less than 1% of patients 
and usually indicates damage to the AV junction or bundle of His26. It is 
therefore more common with anterior wall infarction. The QRS complexes are 
usually narrow, but when widened, they reflect concomitant damage to the 
bundle branches or fascicles and hence more extensive myocardial 
involvement. Risk of progression to complete heart block is high.  
The 2:1 AV block is a specific form of second degree heart block that 
may be due to block within the AV node or the His-Purkinje system. It may be 
either Mobitz type I or Mobitz type II, and this can be established with invasive 
electrophysiologic study.  
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Third-degree (complete) heart block is seen in 5% to 8% of patients 
with acute myocardial infarction and generally occurs early in the course of 
infarction26. Complete heart block is twice as common with inferior or 
posterior wall infarction as with anterior wall involvement27. 
Incidence of intraventricular conduction block 
Intraventricular conduction delays, including bundle branch block and 
fascicular block, occur in about 10% to 20% of patients with myocardial 
involvement28,29. Up to 22% of patients with a new bundle branch block 
progress to a high-grade AV block (ie, Mobitz II or complete heart block). 
Factors associated with an increased risk of complete heart block include a new 
bifascicular block (right bundle branch block plus left anterior fascicular block, 
right bundle branch block plus left posterior fascicular block, or left bundle 
branch block) or a new bifascicular block associated with PR prolongation.  
Prediction of complete heart block 
The Multicenter Investigation of the Limitation of Infarct Size30 
developed a scoring system to predict the occurrence of complete heart block in 
patients with acute myocardial infarction. The incidence of new complete heart 
block was 5.4%, and it occurred a mean of 2.6 days after myocardial infarction. 
Risk of complete heart block was not associated with the location of the 
infarction or the left ventricular ejection fraction. 
The following factors were considered to be predictive of or associated 
with increased risk of complete heart block and were each assigned one point: 
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development of PR prolongation, occurrence of second-degree AV block, left 
anterior or posterior fascicular block, left bundle branch block, and right bundle 
branch block. The risk of progression to complete heart block was 1% to 7% 
with a point score of 0, 8% to 10% with a score of 1, 25% to 30% with a score 
of 2, and 36% with a score of 3 or more.  
Prognosis with complete heart block 
The development of complete heart block is associated with a poor 
prognosis, likely owing to the extensive nature of the acute infarction. In-
hospital mortality for both anterior wall and inferior wall infarction is increased 
by the occurrence of complete heart block, even when other variables are 
accounted for. In-hospital mortality is significantly higher with anterior wall 
infarction (63%) than with inferior wall infarction (42%)27,29. During the first 
year of follow-up, complete heart block in the setting of acute myocardial 
infarction carries a high risk of recurrent AV block and a 28% risk of sudden 
cardiac death. However, as indicated, the high mortality rate is often due to 
pump failure from extensive myocardial damage and not bradyarrhythmias, 
asystole, or tachyarrhythmias. 
Non arrhythmic Complications of Acute Myocardial Infarction30 
Early Complications 
1. Failure of reperfusion 
2. Left ventricular dysfunction and heart failure 
3. Cardiogenic shock 
4. Pericarditis 
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5. Ventricular rupture and ventricular septal defect 
6. Acute mitral regurgitation 
7. Right ventricular failure 
Late Complications 
1. Deep vein thrombosis 
2. Pulmonary embolism 
3. Mural thrombosis and systemic embolism 
4. Left ventricular aneurysm 
5. Dressler's syndrome 
6. Depression 
ECG aids in  i) Prediction of final infarct size 
  ii) Estimation of prognosis of and 
  iii) localization of the culprit vessel. 
ECG findings in acute anterior STEMI 
Precordial leads 
• ST elevation is usually present in V2 to V4 
• ST elevation in V4 to V6 without ST elevation in V1 to V3 usually 
is caused by LCX or distal diagonal occlusion. 
• ST elevation in leads V2 to V6 may represent LAD occlusion 
proximal to the first diagonal branch. 
Leads I and aVL 
• ST elevation in lead I and aVL signifies 
1. Occlusion of a short LAD coronary artery before the first 
diagonal branch (if there is ST elevation in V2 to V4) 
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2. Occlusion of first diagonal branch (if associated with ST 
elevation in V2 and isoelectric ST or ST depression in V3 to V6) 
3. Occlusion of the first marginal branch of the LCX (if there is ST 
depression in V2) 
• ST depression in aVL signifies LAD artery occlusion distal to the 
first diagonal branch. 
Leads II, III and aVF 
• ST depression in the inferior leads signifies 
1. Occlusion of a short LAD coronary artery before the first 
diagonal branch (if there is ST elevation in V2 to V4) 
2. Occlusion of first diagonal branch (if associated with ST 
elevation in V2 and isoelectric ST or ST depression in V3 to V6) 
• ST elevation in the inferior leads signifies occlusion of a long 
LAD artery (that wraps the cardiac apex) distal to the first 
diagonal branch. 
Leads aVR 
• ST elevation in aVR signifies LAD artery occlusion proximal to 
the first septal branch. 
Right bundle-branch block (new) 
• Right bundle-branch block signifies LAD artery occlusion 
proximal to the first septal branch. 
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ECG CRITERIA TO IDENTIFY SITE OF OCCLUSION IN THE LAD32 
 
Crtierion Occlusion Site Sens. Spec. PPA NPA 
CRBBB Proximal to S1 14 100 100 62 
ST ↑ V1>2,5 mm Proximal to S1 12 100 100 61 
ST ↑ avR Proximal to S1 43 95 86 70 
ST ↓ V5 Proximal to S1 17 98 88 62 
Q avL Proximal to D1 44 85 67 69 
ST ↓ II > 1.0mm Proximal to S1/D1 34 98 93 68 
Q V5 Distal to S1 24 93 71 53 
ST ↓ avL Distal to D1 22 95 87 46 
No ST ↓ III Distal to S1/D1 41 95 92 53 
 
Abbreviations :  NPA =  Negative predictive accuracy 
 PPA = Positive predictive accuracy 
 RBBB = Right bundle branch block. 
RISK STRATIFICATION FOR ARRHYTHMIC DEATH AFTER 
ACUTE ANTERIOR WALL MYOCARDIAL INFARCTION 
The process of risk stratification in a patient who has had an acute 
myocardial infarction has 2 components: 
i. Early in-hospital identification of patients at increased risk for recurrent 
ischemic events. 
ii. Identification of patients at increased risk for arrhythmic or 
nonarrhythmic death. 
Risk appears to be equivalent in patients with ST elevation (Q  wave) 
and non ST-elevation (Non-Q wave) infarction. 
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Risk factors 
1. Reduced LVEF (LV ejection fraction) 
2. Ventricular tachycardia induced by electrophysiological study 
(EPS). 
3. Spontaneous ventricular premature beats (VPBs) and non 
sustained (NSVT) ventricular tachycardia documented on 24 
hours ambulatory monitoring 
4. Late potentials on a signal averaged ECG (SAECG) 
5. Reduced heart rate (HRV) variability assessed by ambulatory 
monitoring 
6. T wave Repolarisation alternans (TWA) 
Risk stratification34 
 Following recovery from AMI 6 weeks after the event, long term 
prognosis can be assessed by the following methods: 
1. Ambulatory ECG monitoring 
2. Exercise testing 
3. Signal averaged ECG 
SAECG reveals presence of late potentials that are low-amplitude, high-
frequency wave forms within the terminal portion of the QRS complexes. Late 
potentials reflect the presence of slow conduction within the ventricular 
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myocardium that may serve as a substrate for arrhythmogenesis. The  
underlying histology is hypothesized to be areas of fibrosis interspersed among  
areas of viable myocardium. Currently it is well established that β-blockers and 
successful thrombolysis / revascularization reduce the prevalence of late 
potentials after acute myocardial infarctions. The prognostic power of late 
potentials is diminished. With contemporary aggressive treatment for acute 
myocardial infarction the routine use of SAECG for risk stratification is not 
recommended. 
Clinical implications of the No-Reflow phenomenon35 
 The No-reflow phenomenon occurs after the myocytes in the area are 
already dead and therefore, later recovery of function is almost impossible. 
Patients with the above phenomenon form the highest risk subgroup of patients 
undergoing reperfusion, with raised associated risk of early and sustained 
congestive heart failure and death. 
A large region of no-reflow might impede the ability of the infarct to 
heal and prevent delivery of pharmacologic agents into that area. Follow up 
studies have documented that the no-reflow phenomenon is associated with 
malignant arrhythmias, reduced ejection fraction and a raised risk of cardiac 
death. 
Women with acute myocardial infarction 
 Women have a 56% excess risk for early mortality after a first 
transmural MI than men. 
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ATYPICAL MYOCARDIAL INFARCTION 
• Most prevalent in women above 65 years. 
• High suspicion index needed for diagnosis 
• Common manifestations are 
- Abdominal pain 
- Dyspnoea and 
- Pulmonary edema 
• Incidence of complications, both arrhythmic and non arrhythmic is 
more 
• Mortality rate in Atypical MI is higher than that in Typical MI. 
MI in elderly 
 Death rate is elderly patients with AMI was more than that in younger 
patients with MI. 
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MATERIALS AND METHODS 
 100 consecutive patients with acute anterior wall myocardial infarction 
admitted to the intensive coronary care unit of Stanley Medical College 
Hospital were studied over a period of 9 months. 
The diagnosis of acute myocardial infarction was confirmed with 
1. History 
 Classical chest pain-central retrosternal, constricting, oppressive or 
burning type of pain usually associated with sweating, often radiating to the 
inner aspect of the left arm or shoulder or to the root of the neck occurring 
within 48 hours preceding admission. Patients with h/o prior MI, prexisting 
valvular heart diseases, prior cardiac surgeries and those who had taken 
treatment out side were excluded. 
2. Electrocardiogram 
Electrocardiogram was done in all patients irrespective of symptoms and 
was considered as the definite evidence of acute myocardial infarction. 
3. Bio chemistry 
 Specific tests CPK-MB-Creatine Phosphokinase fraction specific for 
myocardial damage was done in all patients Significant levels -->10 
IU/L. 
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Other Tests 
 Blood urea, Blood sugar and serum creatinine were done for all patients. 
SGOT (AST) / serum Aspartate Transaminase level was done for all 
patients. 
Study protocol during Hospital stay 
 The data regarding the illness of the patients who were admitted was 
entered into a proforma which included 
a. History of symptoms 
b. Risk factors 
c. Family history and past history of similar illness 
d. Physical examination 
e. ECG recording  
f. Investigations 
a. History of symptoms 
 Angina was diagnosed from the typical history of chest pain. 
b. Risk factors 
 Patients were considered over weight if the BMI-Body Mass Index was 
greater than 27 kg/m2 and obese if BMI was more than 30 kg/m2. 
 Patients who currently smoke more than 10 cigarettes per day or any 
number of cigarettes for longer than 6 months were considered as smokers. 
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Patients were considered hypertensive if the blood pressure recorded 
was more than 140 mmHg systolic and 90 mmHg diastolic on more than 2 
occasions; or evidence of end organ damage such as left ventricular 
dysfunction, renal function impairment (or) fundus changes suggestive of  
hypertensive retinopathy were present. 
Patient was considered diabetic if the fasting blood sugar value was 
greater than 126 mg/dl, and post prandial blood sugar was more than 200 
mg/dl. History of alcohol intake was elicited; menstrual history was recorded in 
all females. 
c. Family history 
 Family history of atherosclerotic heart disease was defined as "positive" 
if any first degree relative of the patient had angina pectoris or myocardial 
infarction. A history of hyperlipidaemia during admission or raised serum 
cholesterol above 250 mg% during hospitalisation were considered. 
d. Physical examination 
 A detailed clinical examination including general physical examination, 
jugular venous pressure and waveforms nature and position of apical impulse 
were noted. Careful auscultation of the heart was made to note rate, rhythm and 
other abnormalities. 
f. ECG recording 
 A 12 lead ECG was taken in all patients. The ECG recordings were done 
immediately on admission, 1 hour after thrombolysis, once daily, whenever 
complications arise and at discharge. 
  
34 
ECG Evidence was taken as the following 
QwMI: 
1. ST-T changes with tall peaked "T" waves in hyper acute phase 
followed by "T" inversion. 
2. Deep Q waves more than 0.04 seconds duration and  more than ¼ of 
the height of the following "R" wave in appropriate leads. 
NQwMI: 
 ST segment and T wave changes, chest pain and SGOT/CPK-MB 
elevations. 
Anterior Wall 
 Anteroseptal – V1-V3 
 Anterior – V1-V6 
 Extensive Anterior Wall-V1-V6, 1, aVL 
 Lateral Wall-V4-V5-V6 
 High Lateral Wall-1 aVL 
Pulse, blood pressure (non-invasive), respiratory rate and rhythm, SaO2 
and ECG were continuously monitored in the ICCU. 
Stable patients were transferred to the general medical wards. Stay in 
ICCU-shortest period was 48 hours and longest period was 12 days. The stay in 
general ward was 5 days (shortest period) to 15 days (longest period). 
  
35 
ECG criteria for diagnosis of various arrhythmias 
1.  Sinus tachycardia 
 Heart rate >100 /mt 
 Normal 'P' wave 
 Normal 'PR' interval 
2. Sinus bradycardia 
 Heart rate < 60 /mt 
 Normal 'P' wave 
 Normal 'PR' interval 
3. Premature Atrial Beats (APD) 
i. A 'P' wave that occurs before the next expected series of 
impulses. 
ii. The change in the vector of the early 'P' wave. 
iii. The PR for the conducted APD is usually normal (or) minimally 
prolonged. 
iv. Superimposition of the premature P on the T wave of the 
preceding sinus impulse 
v. An unexpected pause due to failure of conduction of a APD to 
the ventricles. 
vi. The hall mark of timing of APD's is the less then fully 
compensated pause. 
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vii. Careful inspection of T wave of the sinus impulse before APD 
will reveal a distortion of the T wave. 
4. Supeaventricular tachycardias 
 - Atrial rate of more than 100 / mt 
 - Ventricular rate may be less when AV conduction is incomplete 
 - Narrow QRS complexes 
 - QRS complexes may be wide if there is aberrant conduction through a 
bypass tract. 
 - May be paraxysmal / persistent / chronic. 
5. Ectopic atrial tachycardia 
 - Usually persistent 
 - P waves are usually normal but not clearly evident when the 
ventricular rate is rapid. 
 - With carotid sinus massage, P waves are more evident 
6. Multifocal Atrial tachycardia 
1. P waves having 3 or more different morphologies that occur in 
different cycle lengths with marked variations in PP intervals. 
2. The rhythm is usually chaotic but rate less than 140/mt 
3. Frequent APD present 
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7. Atrial Flutter 
1. A saw tooth pattern in inferior leads. 
2. The electrical activity appears continuous without a defined 
isoelectric line between waves. 
3. The most common AV conduction ratios in atrial flutter are 2:1 
and 4:1 
4. A narrow QRS tachycardia at a rate of 150/mt should always lead 
to the consideration of Atrial flutter. Carotid sinus massage may 
be helpful in unconvering atrial flutter. 
8. Atrial fibrillation 
1. Irregular atrial electrical activity with respect to both rate and rhythm 
2. Fibrillatory waves are clearly evident 
3. Absent 'P' waves and varying RR intervals 
9. AV Junctional Rhythm disturbances 
1. Premature AV junctional impulses 
2. Junctional rhythm 
3. Accelerated junctional rhythms 
4. AV junctional tachycardias 
The normal inherent rate of AV junctional automatic activity is 40-
60/mt. Faster rates from, these levels are considered 'accelerated' rhythms upto 
100/mt, after which they are considered 'tachycardia'. 
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Ventricular Arrhythmias 
10. VPD 
1. QRS complex is premature, wide and often bizarre in appearance. 
2. ST and T wave are opposite in direction to the QRS 
3. No premature P wave precedes the premature QRS complex. 
4. The pause after VPD is fully compensatory 
5. If very premature, 'R' wave of the premature beat occurs on the apex of 
'T' of the previous complex (R on T phenomenon). 
6. The VPD may be so late that it fuses with the subsequent QRS complex. 
7. If the VPD captures the SA node, then the pause will be less than 
compensatory. 
8. The VPD may be interpolated –when the sinus rhythm is slow, the VPD 
is premature and its retrograde conduction is blocked at the AV node. 
here is prolongation of PR of the subsequent complex. 
9. If the coupling intervals are fixed, then the mechanism is reentry. 
10. Coupling intervals can vary markedly when a parasystolic ventricular 
rhythm is present (or) there is substantial instability in a reentrant circuit 
(or) when VPD's are multifocal. 
11. When every other QRS is a VPD, it is called bigeminy and when every 
3rd QRS is a VPD, it is called trigeminy; when every 4th QRS is a VPD, 
it is called quadrigeminy. 
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12. 2 successive VPD's are called couplets. 
Lown et al. believed that VPC's predispose to ventricular fibrillation and 
graded the VPC's as follows: 
Grade  O : No VPC's 
 I : Less than 30 VPC's / hours 
 II : More than 30 VPC's / hour 
 III : Multifocal VPC's 
 IV-A : Coupled VPC's / Bigminy 
 IV-B : Salvos of 3 or more (UT) 
 V : R on T phenomenon 
11. Ventricular tachycardia 
 3 or more VPD's in succession at a rate of more than 140-200 cycles/mt 
12. Ventricular capture 
If the rate of VT is not very rapid occasional sinus impulses may capture 
the ventricles producing a normal QRS complex. 
Fusion Complex 
If the rate of VT is not very rapid a QRS complex intermediate in 
contour between a normal QRs and that of ventricular tachycardia occurs. 
Accelerated indioventricular rhythm 
 3 or more consecutive QRS complexes of ventricular origin with a rate 
between 50 and 100 cycles/mt. 
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Twice as common in inferior infarct; common during Reperfusion 
therapy. 
13. Ventricular parasystole 
 Automatic rhythm in the ventricles that is reasonably independent of the 
sinus rhythm. 
 Varying coupling of VPD's and a common denominator for interectopic 
intervals. 
Ventricular flutter 
 Ventricular tachycarrhythmias more than 200/mt (usually 240-280/mt) 
large sinusoidal / zigzag waves present. 
15. Ventricular fibrillation 
 Absence of QRS complexes and T. Waves presence of low amplitude 
baseline undulations. 
CONDUCTION DISTURBANCES 
16. SA Block 
 Simulates sinus bradycardia 
 Absent 'P' wave and 'QRS' complex intermittently. 
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17. AV Block 
 I° AV Block – All atrial impulses are conducted to the ventricles with 
delay - seen in ECG as prolonged PR intervals. 
 II° AV Block – Few atrial impulses are conducted to the ventricles. Few 
are not conducted. 
 Mobitz type 1 AV block – Wenkebach phenomenon 
ECG shows progressive prolongation of the PR interval followed by a 
missed beat. 
Mobitz type 2 AV block 
Intermittent missed beats seen in the ECG with no preceding 
prolongation of PR interval. 
III° AV Block 
None of the atrial impulses are conducted to the ventricles. 
ECG shows complete AV dissociation. 
Criteria for Right Bundle Branch Block 
Lead V1    Late intrinsicoid, M-shaped QRS (RSR'); sometimes wide R or qR 
Lead V6   Early intrinsicoid, wide S wave 
Lead 1     Wide S wave 
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Criteria for Left Bundle Branch Block 
Lead V1    QS or rS 
Lead V6   Late intrinsicoid, no Q waves, monophasic R 
Lead 1     Monophasic R wave, no Q 
Criteria for Left Anterior Fascicular Block  
1. Left axis deviation (usually ≥ – 60 degrees) 
2. Small Q in leads I and aVL, small R in II, III and aVF 
3. Usually normal QRS duration 
4. Late intrinsicoid deflection in aVL (>0.045 s) 
5. Increased QRS voltage in limb leads 
Criteria for Left Posterior Fascicular Block  
1. Right axis deviation (usually ≥ + 120 degrees) 
2. Small R in leads I and aVL, small Q in II, III and aVF 
3. Usually normal QRS duration 
4. Late intrinsicoid deflection in aVL (>0.045 s) 
5. Increased QRS voltage in limb leads 
6. No evidence for right ventricular hypertrophy 
e. Biochemical investigation 
Biochemical investigation done at the time of admission are listed 
below. They were also repeated as and when necessary; Values considered 
normal in our study are given below. 
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1. Urine Analysis  : Albumin-nil, Sugar-nil 
2. Haemoglobin  : More than 10 mg/dl 
3. Blood sugar fasting : 80-100 mg% 
 Postprandial  : 100-140 mg % 
4. Blood Urea  : 20-40 mg % 
5. CPK-MB   : Upto 10 IU/Lit 
6. SGOT   : Upto 40 IU/Lit 
7. Serum Cholesterol : 150-240 mg % 
CHEST X-RAY 
X-ray chest PA view was done to look for cardiomegaly, pulmonary 
congestion and hydrothorax. 
At discharge a detailed clinical examination with special reference to 
pulse rate, blood pressure and general condition of the patient were noted and 
the ECG repeated. 
Patients were reviewed every week for 1 month and thereafter every 15 
days at the cardiology out patient department. 
ECHO was done for all patients admitted to the ICCU with acute MI and 
the following parameters studied: 
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1. Regional wall motion abnormalities 
2. Left ventricular systolic and diastolic functions. 
3. Left ventricular ejection fraction. 
4. Left ventricular dimensions. 
5. Presence of left ventricular mural thrombus 
6. Presence of LV aneurysm 
7. Presence of MR/VSD (and) 
8. Presence of pericardial effusion 
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RESULTS AND OBSERVATIONS 
Total number of patients with acute myocardial infarction under study = 
100. 
Table 1 
Arrhythmias in acute AWMI 
 
No. of patients with 
Arrhythmias 
No. of patients without 
arrhythmias 
72 28 
 
 72% of the patients with acute anterior wall MI had arrhytmias. 
Table 2 
Sex distribution of acute anterior wall MI 
Male Female 
75 25 
 
 Total No. of males with Acute AWMI = 75 
 
 Total No. of females with Acute AWMI = 25 
 
Table 3 
Sex distribution of Arrhythmias in acute AWMI 
No. of males 
with ARR 
% of males No. of females 
with ARR 
% of females 
55 73.33% 17 68% 
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 Total no. of males with acute AWMI with arrhythmias = 55 patients = 
73.33% of males with AWMI. 
Total no. of females with acute AWMI with arrhythmias = 17 patients = 
68% of females with AWMI. 
Study shows that males had higher incidence of acute AWMI and the 
resultant arrhythmias. 
Table 4 
Age and sex distribution and incidence of arrhythmias 
Incidence of MI 
(No. of patients) Incidence of Arrhythmias % Age group 
Male Female T Male Female T 
31-40 7 - 7 2 (28%) - 2% 
41-50 21 2 23 16 (76%) - 16% 
51-60 22 10 32 16 (73%) 7 (70%) 23% 
61-70 17 7 24 13 (76%) 4 (57%) 17% 
71-80 8 6 14 8 (100%) 6 (100%) 14% 
 75 25 100 55 (73%) 17 (68%) 72% 
 
 Youngest patient recorded  - 26 yr. male 
 Oldest patient recorded – 85 yr. male 
 The highest incidence of AMI and the resultant arrhythmias was 
observed in the age group (51-60) yrs. in both males and females. 
 The incidence of arrhythmias increases with age from 41-80 yrs. 
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Table 5 
Sex distribution in relation to location of MI 
Sex Antero 
septal 
Anterior wall 
with inferior 
wall 
Anterior 
wall 
Extensive 
anterior 
wall 
Antero 
Lateral 
wall 
Male 35 1 26 12 1 
Female 9 0 10 4 2 
Total 44 1 36 16 3 
 
ASMI was the most common presentation 
Symptom analysis 
 Among 100 patients, 86 were admitted with classical angina and 14 with 
angina equivalents. 
Symptom % 
Chest pain 86% 
Radiation to (lt) shoulder 36% 
Palpitation 19% 
Sweating 29% 
Syncope 10% 
Dyspnoea 32% 
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Table 7 
Risk factor analysis 
Risk factor % 
Smoking 76% 
SHT 49% 
DM 34% 
Alcoholism 46% 
Obesity 6% 
Hyperlipidemia 6% 
Multiple RF 60% 
No. RF 4% 
Post Menopausal 96% 
 
 76 patients with acute AWMI had smoking as RF. All of them were 
males. 
 
Table 8A 
Multiple risk factors 
Multiple % 
Smoking + Alcohol 40% 
DM+SHT+Smoking 10% 
HT+Smoking+Alcohol 10% 
 
 % of patients with acute AWMI having multiple RF = 60%. 
Table 8B 
Single RF % Multiple RF % 
40% 60% 
 
 Of the single RF, smoking was the most common (76%) 
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Table 9 
Multiple RF in relation to prevalence of Arrhythmias 
% with multiple RF % With 
Arrhythmias 
% without 
Arrhythmias 
60% 96.7% 3.3% 
 
Incidence of arrhythmias was more common in patients with multiple 
RF. 
Table 10 
Distribution of arrhythmias in patients with acute AWMI 
S.No. Arrhythmia Number of 
Cases 
1. Sinus Tachycardia 12 
2. Sinus Bradycardia 1 
3. SVT 3 
4. Atrial Ectopics 1 
5. Atrial Fibrillation 4 
6. Ventricular ectopics 35 
  UC (uncomplicated) 13 
  C (complicated with VT,VF) 22 
7. Complete Heart Block 4 
8. SA Block 0 
9. RBBB 3 
10. LBBB 4 
11. RBBB + LAHB 5 
12. No. Arrhythmias 28 
 
 VPD's were the most common arrhythmias (35 cases) complicated by 
VT/VF in 22 cases. 
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Table 11 
S.No. Site of Infarction % 
1. Antero Septal 44% 
2. Anterior Wall 36% 
3. Extensive Anterior Wall 16% 
4. Antero Lateral Wall 3% 
5. High Lateral 0% 
6. Inferior + Anterior Wall 1% 
 
 Among the site of infarction, anteroseptal was the most  common. 
Table 12 
Sex distribution of arrhythmias 
Incidence Total % Male % Female % 
Sinus Tachycardia 12 10 2 
Sinus Bradycardia 1 1 - 
APD 1 1 - 
SVT 3 2 1 
Atrial Fibrillation 4 2 2 
VPD 13 12 1 
VT 14 10 4 
VF 8 6 2 
Complete heart block 4 4 - 
RBBB 3 2 1 
LBBB 4 2 2 
LAHB - - - 
RBBB+LAHB 5 4 1 
No Arrhythmias 28 20 8 
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Table 14 
Incidence as per Western Literature (Ref. 1) 
Sl.No. Arrhythmia % 
1. Sinus bradycardia 40%, 1st Hr., 20% 4 Hrs. 
2. Sinus tachycardia 41% 
3. Atrial ectopics 50% 
4. PSVT 2-5% 
5. Atrial flutter 2-3% 
6. Atrial fibrillation 10-15% 
7. Junctional rhythm 1-2% 
8. Ventricular Ectopics 57% 
9. Ventricular tachycardia 10-40% 
10. AIVR 8-20% (I 2 days) 
11. VF 4-18% 
12. Ventricular Asystole 1-14% 
13. I° AVB 14% 
14. II° AVB 4-10% 
15. III°AVB 5-8% 
16. Intraventricular Blocks 10-20% 
17. LAHB 3-5% 
18. LPHB 1 
19. RBBB 2 
20. LBBB 2 
21. RBBB+LAHB 5 
22. RBBB+LPHB 1 
 
Table 15 
Pathological types of MI 
No. of cases QMI NQMI 
100 68 32 
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Table 16 
Percentage of Arrhythmia in QwMI and Non QwMI 
No. of patients with Arr. % of Arr. Total No. of 
patients with Arr. QMI NQMI QMI NQMI 
72 52 20 72% 28% 
 
Table 18 
Percentage of Mortality in relation to location of MI 
Ext. Anterior wall ASMI AWMI Total 
Mortality No. of cases % No. % No. % 
21 16 76% 3 14% 2 10 
 
Table 19 
Mortality in acute AWMI 
Total no. of deaths Arrhythmias Cardiogenic shock 
21 19 2 
 
Table 20 
Effect of arrhythmias on hemodynamic stability/mortality 
Type of arr. No. of patients Death 
VT/VF 22 20 
AF 4 1 
CHB 4 - 
BBB 12 - 
Total 42 21 
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Table 21 
Thrombolysis in MI 
Total No. of patients with Acute AWMI 100 
No. of patients thrombolysed 72 
No. of patients not thrombolysed 28 
 
Table 21 
Incidence of Arrhythmias in relation to the duration after onset of 
symptoms 
Time (hrs) Acute AWMI Acute AWMI 
with ARR 
% 
0-1 hrs 26 22 84 
1-2 hrs 26 20 76 
2-4 hrs 32 24 75 
4-6 hrs 11 5 45 
> 6 hrs. 5 1 20 
Total 100 72  
 
The patients coming in the initial hours had a higher incidence of 
arrhythmias. 
Table 22 
Sex distribution of mortality 
 
Sex Deaths 
Males 12 
Female 9 
Total 21 
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DISCUSSION 
The findings of our study corroborate well overall with several other 
studies conducted in different parts of the world regarding etiological factors, 
symptomatology, risk factors, clinical features, complications and outcome 
though there are several interesting points of difference in many of these areas, 
which may be attributed to differences in racial, geographical distribution of 
the sample studies as well as to the constraints in facilities available and time 
window when they reach the hospital. 
In a study conducted by the Italian University in 1994, it was found that 
32% of women above 65 kgs presented with atypical angina of which 
abdominal pain, dyspnoea and pulmonary edema were the most frequent 
symptoms39. 
In our study of 100 cases, 25% were women, all of whom were aged 
above 40 years, 25% of them presented with atypical angina (angina 
equivalents) of which dyspnoea was the most frequent symptom. 
In a study conducted by Sri Jayadeva Institute of Cardiology, Bangalore 
(1994)40, women formed 17% of total MI cases, of which 93% were above 40 
years.  
Infarction occurred mostly (96%) in post menopausal period in our 
study. 
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Mortality rate was high (36%) in women. When compared to men 
(16%), the commonest cause being arrhythmias. The percentage of arrhythmias 
in females was significantly less (68%) compared to that of males (73%). 
The facts brought out from our study have general agreement on a 
multifactorial etiology of ischemic heart disease and that incidence of the 
disease increases with age. 
Percentage of patients with multifactorial etiology was 60%, 95% of the 
above patients had arrhythmias, the most common being VPD's. 
Dolder et al. (1975)41 conducted an international study on myocardial 
infarction in Young men. They found that the cause for high incidence of MI in 
the young was the high prevalence of risk factors particularly smoking and 
hyperlipidemia in the west and eigarette smoking and hyperglycaemia in India. 
We also found that the most important risk factors prevalent among the 
younger age groups were eigarette smoking, hypertension and hyperglycaemia. 
The incidence of NQMI in our study was 32% and QMI 68%. The long 
term outcome of NQMI Vs QMI did not differ according to a study by 
Tokushima's cardiology department (1994)42. Long term outcome and 
complications could not be followed up in our study due to the time frame of 
study and poor patient compliance. However mortality in ICCU was more in 
QMI (90%). When compared to NQMI (10%). 
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Regarding immediate outcome and complications, there was a total 21% 
mortality within the first 2 wks of MI, about 50% of this occurring in the first 6 
hours. VF was the leading cause of death in AWMI. 
Compared to the Western study, our mortality rate is still high, partly 
due to the limited facilities for coronary care and partly due to the delay in 
bringing the patients to the ICCU after Acute MI. Only 52% reached hospital in 
the first 2 hours. 
Hospital mortality was high among patients aged above 50 yrs in both 
males and females, compared to those below 50 hrs of age. This observation is 
in agreement with the findings of Gregory et al. 198343. 
Bigger et al. 197844 and Taylor et al. 198045 indicated that the extent of 
left ventricular damage is a major determinant of survival in patients following 
Acute MI. We also found that the mortality rate was high when the extent of 
infarction was more. 70% mortality was in extensive AWMI. 
Incidence of VT was 14% as compared to the 10% in the study of Bell et 
al. 197246. Incidence of VF was 8% in our study as compared to 10% according 
to Kertes et al. 1984 and 3-5% reported by Garg et al.47 
Garg et al. (1984)47 believed that when there was extensive infarction, 
there was greater chance for the reentry mechanism to operate, resulting in the 
genesis of Arrhythmias. 
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Incidence of VPC's (both complicated and uncomplicated) were found 
to be 35% in our study compared to 36% in textbook of cardiology by 
Braunwald,48 57% reported by Arthur more and 70% by Morrison et al.49 
Completed heart block was observed in 4 patients out of 100 cases 
which is consistent with 5% suggested by Braunwald. 
Incidence of sinus tachycardia was 12% in our study, as compared to the 
study of Lours  et al. 196750, Jewitt et al. 196751 which suggest an incidence of 
30%. 
Regarding adjunctive medical therapy for acute MI, Trauma medical 
centre, Kansas52 (1994) advocated oxygen, morphine, nitrates, beta blockers, 
ACEI and Aspirin. IV heparin and magnesium therapy have been advised in 
special subsets of the patients thrombolysed with IV streptokinase 75% of them 
developed AIVR, 20% had S.bradycardia & 5% had conduction defects. 
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CONCLUSION 
 Incidence of Myocardial infarction increases with age. 
 Incidence of Myocardial infarction is significantly more in men (75%) 
compared to that in women (25%). 
 In women, Acute MI was observed mostly (96%) in the post 
menopausal group 
 Smoking was the most common Risk factor (76%). 
 Hypertension and Diabetes mellitus were the most important risk factors 
in females. 
 Atypical chest pain was more common in females, of which dyspnoea 
was the most frequent. 
 Mortality was higher in older patients  
 Cardiac failure and cardiogenic shock were associated with poor 
prognosis. 
 Most common arrhythmia in our study was VPD's 
 Arrhythmias are more common in males (73%) against (68%) in 
females. 
 Arrhythmias are more common in those over 45 yrs (97%). The 
tachyarrhythmias had a higher incidence. 
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 Arrhythmias are more common with multiple risk factors (96%). 
 Most benign arrhythmia was occasional VPD's. 
 Most dangerous arrhythmia was VF 
 Atrial flutter, parasystole and I & II° AVB were not recorded seen in our 
study. 
 Total mortality was 21% of which death was more common in QMI 
(90%) and Non QMI (10%). 
 Extent and the size of infarct had a direct correlation to mortality 
The present study has enabled us to identify the high risk group for 
observation and follow up. 
Risk stratification helps us in early identification of complications and 
its treatment. The judicious use of interventional surgical and non surgical 
approaches with life style modification may pave way for revolutionary 
changes in mortality and morbidity in patients with arrthymias in acute anterior 
wall MI. 
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PROFORMA 
Sl.No. 
Name 
Age 
Sex 
DOA 
DOD 
Occupation 
IP No. 
SYMPTOMATOLOGY 
Angina 
Radiation 
Sweating 
Palpitations 
Breathlessness 
Syncope 
RISK FACTORS 
Obesity 
IHD 
DM 
SHT 
Smoking 
Alcoholism 
H/o. CVA 
OCP 
Menopausal 
Hypercholesterolemia 
FAMILY HISTORY 
IHD 
DM 
SHT 
CVA 
SCD 
ON EXAMINATION 
PR 
Rhythm 
BP 
Temp C 
Anaemia 
Cyanosis 
Sweating 
PE 
Markers of Atherosclerosis 
JVP 
CVS PALPATION 
AI 
Thrill 
Palpable sounds 
CVS AUSCULTATION 
S1 
S2 
S3 
S4 
Murmurs 
Rub 
RS 
Added Sounds 
ABDOMEN 
FF 
Organomegaly 
CNS 
INVESTIGATIONS 
Se.Cholesterol 
SGOT 
CPK-MB 
CRP 
Urea 
Sugar 
Creatinine 
ECG 
CXR 
ECHO 
TREATMENT 
Thrombolysed 
Nasal O2 
Sedation 
Anticoagulants 
Anti failure Drugs 
Anti Arrhythmics 
Vaso dilators 
Others 
Defibrillation 
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 26 28
1 Manga Lakshmi 65 F 5.1.07 2 528 - + - + - - + - - - - + + 90 R S ASMI VPD + - - -
2 Sulochana 70 F 16.1.07 4 1520 - + + + - - + + - - - + + 142 IR S ASMI AF + - + -
3 Nataraj 52 M 16.1.07 3 1590 + - - - - + - - + + + - - 96 R S EAWMI RBBB + + - -
4 Govindaraj 42 M 16.1.07 1 1598 + - - + - - - + + + + - - 80 IR S ASMI VPD + + + -
5 Abdul Razak 48 M 17.1.07 4 1697 + + + - - + + - + + + - - 112 R IS ASMI ST + + - -
6 Komalavalli 55 F 17.1.07 3 1743 - + + + - - + + - - - + - 80 R IS EAWMI LBBB + + - -
7 Selvaraj 40 M 22.1.07 2 2269 + - + + - - - - + + + - - 30 IR S AIMI CHB + + TP -
8 Kuppam 50 M 27.1.07 4 2826 + - - - - - - - + + + - - 96 R S ASMI ST + + - -
9 Janaki 60 F 2.2.07 4 3305 + + + + - - + + + - - + + 146 R S AWMI SVT + + - -
10 Ragaiah 74 M 3.2.07 7 3694 + - - + - - - - + + + - - 98 R S AWMI BFB + + - -
11 Arunachalam 65 M 4.2.07 6 3740 + - - + + - - - + + + - - 90 R S ALMI VPD + + - -
12 Shankar 45 M 9.2.07 3 4371 + + - - - - + - + - - - - 88 IR S AWMI VPD + + + -
13 Loganathan 64 M 10.2.07 5 4508 + - + + - - - + + + + - - 128 R S ASMI SVT + - + -
14 Nasariah 60 M 12.2.07 4 4684 + - + - - - - + + + + - - 80 R S ASMI - + - - -
15 Mariyappan 62 M 15.2.07 1 5070 + - - + + - - - + - - - - 74 R S AWMI VPD + - + +
16 Kayanchi 55 M 17.2.07 2 5376 + - - - - - - + + + + - - 140 R IS AWMI - + - - -
17 Bhavani Dasan 46 M 22.2.07 4 5835 + - + - - + - - + + + - - 80 R S ASMI VPD + + - -
18 Karpagaraj 53 M 22.2.07 2 5950 + - + + - + - + + + - - + 96 R S ASMI VT + + - -
19 Mohan Kumar 47 M 24.2.07 5 6087 + - - + - - - - + + - - - 82 R S EAWMI BFB + + - -
20 Munusamy 54 M 24.2.07 3 6070 + - - - - - - - + + + - - 84 R S AWMI - + + - -
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21 Shahul Hameed 66 M 26.2.07 6 6334 + - - + + - + + - - - - 106 R S AWMI ST + + - -
22 Umar Jahn 58 M 27.2.06 4 6404 + - - - + - - - + + + - - 111 R S EAWMI ST + + - -
23 Vella Thai 60 F 28.02.07 2 6638 - - + + - - - + - - - + - 120 R S AWMI VT + - + +
24 Govindammal 85 F 2.03.07 2 6804 - + - - - - + - - - + + + 116 R S AWMI VF + - + +
25 Narayanasamy 70 M 9.03.07 3 7633 + - + - + - - + + + - - - 144 R S ASMI VT + + + +
26 Venkatesan 42 M 10.03.07 4 7818 - + - + - - + - - + - - - 68 R S ASMI - + + - -
27 Mohan Kumar 75 M 10.03.07 1 7908 + - - - - + - - + + + - - 146 R S ASMI SVT + - + -
28 Joseph John 48 M 12.03.07 40 min 8122 + - - + - - - + + + - - - 74 R S AWMI - + + - -
29 Tharamani 52 F 16.03.07 1 hr. 8597 + - - + - - - - + - - + - 154 IR S ASMI AF + + + -
30 Kalyana Sundaram 54 M 18.03.07 2 hr. 8745 + + + - - - + + + + + - - 88 R S EAWMI - + + - -
31 Krishnan 70 M 28.3.07 3 10025 - + - + - + + - - + + - - 80 R S ASMI LBBB + - - -
32 Venkataiah 65 M 28.3.07 2 10026 - + + + - - + + - + - - - 76 R S ASMI - + - - -
33 Elizabeth 60 F 30.3.07 3 10286 + - - - - - - - + - - + - 80 R S AWMI - + + - -
34 Deivasigamani 65 M 30.3.07 1 10523 + - - + - - - - + + + - - 140 R S ASMI VT + + + +
35 Rajeshwari 65 F 1.4.07 5 10528 + + - - - - + + + - - + - 96 R S AWMI - + - - -
36 Raghupathy 70 F 2.4.07 2 10584 - + - + - - + - - + - - - 136 R S ASMI VF + + + +
37 Purushothaman 56 M 13.4.07 6 11845 + - - + - - - + + + - - - 101 R S ALMI ST + - - -
38 Pooammal 65 F 13.4.07 8 11946 + - - - - - - - + - + + - 110 R S AWMI ST + + - -
39 Ramammal 60 F 14.4.07 1 12959 + + + - - - + + + - - + + 124 R S EAWMI VF + + + +
40 Ramu 50 M 21.4.07 1 12974 + - - - - - - - + + + - - 80 R S AWMI - - + - -
41 Yuvaraj 41 M 23.4.07 2 13068 + - - - + - - - + - - - - 82 R S AWMI SB - - - -
42 Rukmaniammal 64 F 27.4.07 3 13525 + + - - - - + - + - - + + 110 R S EAWMI VT + + + +
43 Munusamy 40 M 27.4.07 2 13526 + - + + - - - + + - + - - 80 R S EAWMI - + + - -
44 Sampath 70 M 27.4.07 1 13565 + - + - - - - + + + - - - 90 R S ASMI - + + - -
45 Pushpammal 80 F 4.5.07 1 16363 + - - + + - - - + - - + - 94 R S EAWMI - + - - -
46 Ramalingam 63 M 4.5.07 1 14378 + - - - - - - - + + + - - 106 R IS ASMI VT + - + +
47 Maliga Behum 54 F 4.5.07 1 14442 + - - - - - - - + + + - - 90 R S ASMI VF + - + +
48 Selvam 43 F 5.5.07 3 14842 + - - + - - - - + + - - - 94 R S EAWMI ST + + - -
49 Thangaraj 37 M 9.5.07 4 15084 + - - + - - - + + + - - - 88 R S EAWMI VPD + + - -
50 Saradha 75 F 11.5.07 2 15295 + - - - - - - - + - + + - 90 R IS ASMI - + - - -
51 Raja Kahn 45 M 12.5.07 5 15371 + - - - - - - + - - - - 96 IR S ASMI VPD + + - -
52 Karunakaran 50 M 13.5.07 1 15606 + - - - + - - - + + - - - 90 IR S ASMI APB - - - -
53 Ramachandran 55 M 13.5.07 2 15830 - - + + - - - + - + - - - 114 R S AWMI - - + - -
54 Natarajan 65 M 15.5.07 3 15920 - + - - - - + - - + + - - 88 R S ASMI ST + + - -
55 Manickam 55 M 15.5.07 3 15923 + - + - + - - + + - - - - 112 IR S ASMI VPD + + + +
56 Syed Basha 74 M 15.5.07 2 16173 - + - + - - + - - - - - - 80 R S ASMI ST + + - -
57 Santhosh 49 M 17.5.07 3 16423 + - - - - + - - + + + - - 78 R S EAWMI - + + - -
58 Ramamoorthy 57 M 10.5.07 3 16521 + - - - - - - - + - - - - 136 R S AWMI AF + + + +
59 Ezhumalai 50 M 21.5.07 3 16910 + - - + - - - - + + - - - 80 IR S AWMI - + + - -
60 Ravi 53 M 23.5.07 4 16926 + + + - - - + + + + - - - 150 R S ASMI VT + - + +
61 Poonusamy 63 M 25.5.07 2 17118 + - - - - - - - + + + - - 80 R S AWMI VPD + + - -
62 Ramamoorthy 57 M 25.5.07 1 16521 + - - - + - - - + + - - - 130 R S ASMI VF + - + +
63 Velayudham 65 M 25.5.07 3 17192 + + - - - - + - + + + - + 80 R S EAWMI VPD + + - -
64 Bee Bee John 80 F 26.5.07 3 17236 + - + + - - - + + - - + - 112 R IS ASMI VT - - + +
65 Shanthi 50 F 31.5.07 6 17828 + - + - - - - + + - - + - 70 R S ASMI - - + - -
66 Narayanan 44 M 4.6.07 5 18275 + - - + + - - - + + - - - 68 R S EAWMI - + + - -
67 Soundarajan 47 M 10.6.07 4 18442 + - - - - - - - + + + - - 70 R S ASMI VPD + + - -
68 Mangalamary 60 F 14.6.07 3 19125 + - - - - - - - + - - + - 110 R S AWMI ST + + - -
69 Dhanapal 26 M 16.6.07 2 19751 + - - + - - - - + + - - - 80 R S ASMI - + + - -
70 Manohar 53 M 17.6.07 1 19981 + - - + - - - - + + + - - 106 R S AWMI ST + + - -
71 Mohan Kumar 52 M 18.6.07 2 20033 + - - - - - - - + + - - - 36 R IS ASMI CHB - + TP -
72 Nagarathinam 60 F 23.6.07 ½ 20184 + - - - - - - + - + + - 112 R S ASMI BFB + + - -
73 Mehboob 76 M 25.6.07 1 20891 + - - - + - - - + - - - - 140 IR S AWMI LBBB + - - -
74 Arjunan 75 M 28.6.07 ½ 20938 - - + + - - - + - - - - - 106 R S ASMI VT + - + +
75 Chandran 55 M 28.6.07 2 21479 - + - - - - + - - + + - - 80 R S ASMI - + + - -
76 Chinnasamy 45 M 30.6.07 1 21485 + - + - + + - + + + + - - 36 IR IS ASMI CHB + + TP -
77 Suresh 44 M 1.7.07 2 21616 - + - + - - + - - + + - - 130 R S AWMI AF + + + -
78 Natarajan 36 M 1.7.07 2 21714 + - - - - - - - + + - - - 88 IR S ASMI - + + - -
79 Abiyan 38 M 4.7.07 1 21719 + - - - - - - - + + - - - 90 IR S ASMI - + + - -
80 Marimuthu 85 M 9.7.07 3 22123 + - - + - - - - + + + - - 84 R S EAWMI BFB + + - -
81 Radhakrishnan 80 M 11.7.07 4 22893 + + + - - - + + + + - - - 78 R S EAWMI VPD + - - -
82 Chandrasekar 50 M 14.7.07 3 23058 + - - - - - - - + + + - - 70 R S AWMI BFB + + - -
83 Maniammal 60 F 15.7.07 ½ 23510 + - - - + - - - + - - + - 68 R S AWMI VT + - + +
84 Ellammal 65 F 25.7.07 2 23564 + + - - - - + - + - - + - 90 R S AWMI RBBB + - - -
85 Muthu Mary 45 F 27.7.07 2 24890 + - + + - - - + + - - - - 92 R S AWMI - + + - -
86 Mannicbasha 81 M 31.7.07 2 25284 + - + - - - - + + + + - - 90 R S ASMI RBBB + + - -
87 Poonusamy 56 M 1.8.07 1 25249 + - - + + - - - + + - - - 112 R IS AWMI VF + - + +
88 Nithyananthan 44 M 1.8.07 ½ 25755 + - - - - - - - + + - - - 106 R IS AWMI VT + - + +
89 Raghupathy 70 M 2.8.07 1 25804 + - - - - - - - + + + - - 124 R S ASMI VT - + + +
90 Shankar 60 M 2.8.07 1 25967 + - - + - - - - + + + - - 112 R S AWMI ST - - - -
91 Susheela 80 F 9.8.07 1 25983 + - - + - - - - + - - + - 94 R IS AWMI BFB - - - -
92 Dilip Kumar 28 M 17.8.07 2 26872 + - - - - - - - + + - - - 106 R IS ASMI - + + - -
93 Abdul Wakan 60 M 21.8.07 3 27855 + - - - - - - + + + - - 90 R S ASMI - + + - -
94 Kuppan 55 M 21.8.07 3 28264 + - - - + + - - + + - - - 88 R S AWMI VT + + + +
95 Thambiraj 70 M 6.9.07 3 30088 - - + + - - - + - + + - - 40 R IS AWMI CHB + + TP -
96 Selvan 64 M 7.9.07 4 30223 - + - - - - + - - + + - - 76 R IS AWMI BFB + + - -
97 Susheela 67 F 8.9.07 2 40443 + - + - + + - + + - - + - 90 IR S ALMI - + + - -
98 Thavarammal 75 F 9.9.07 6 30539 - + - + - - + - - - - + - 96 R S AWMI - + - - -
99 Saraswathy 60 F 10.9.07 8 30686 + - - - - + - - + - - + - 94 R S ASMI - + + - -
100 Mani 52 M 12.9.07 1 30879 + - - - - + - - + + + - - 130 R S AWMI VT + - + +
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